Back to Journals » Clinical Pharmacology: Advances and Applications » Volume 12

Hydroxychloroquine in COVID-19: The Study Points to Premature Decisions on Efficacy While Bells Ringing for Safety

Authors Khadka S, Shrestha DB, Budhathoki P, Rawal E

Received 24 June 2020

Accepted for publication 4 August 2020

Published 17 August 2020 Volume 2020:12 Pages 115—121

DOI https://doi.org/10.2147/CPAA.S269156

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Arthur Frankel


Sitaram Khadka,1 Dhan Bahadur Shrestha,2 Pravash Budhathoki,3 Era Rawal4

1Department of Pharmacy, Shree Birendra Hospital; Nepalese Army Institute of Health Sciences, Kathmandu 44600, Nepal; 2Department of Emergency Medicine and General Practice, Mangalbare Hospital, Morang 56600, Nepal; 3Department of Emergency Medicine and General Practice, Dr Iwamura Memorial Hospital, Bhaktapur 44800, Nepal; 4Department of Emergency Medicine and General Practice, Kathmandu Medical College, Kathmandu 44600, Nepal

Correspondence: Sitaram Khadka
Department of Pharmacy, Shree Birendra Hospital; Nepalese Army Institute of Health Sciences, Kathmandu 44600, Nepal
Tel +00977-9851077589
Email sitaram.khadka@naihs.edu.np

Abstract: Coronavirus disease (COVID-19) pandemic has been a global disease burden. It has affected more than sixteen million people in the world within seven months of its first outbreak in Wuhan. Different treatment modalities, therapeutic and prophylactic agents for its therapy are underway. Until the proven therapy gets available, repurposing of drugs is a better way out. Hydroxychloroquine (HCQ) has been a potential recourse of treatment in this regard for COVID-19 management. As different episodes of cardiac adverse events of HCQ are reported, safety concerns are now a prime objective. The risk-benefit analysis is mandatory to address rational drug therapy even in such a global health crisis. In this article, we want to evaluate the safety and efficacy of HCQ in COVID-19 management.

Keywords: cardiac arrhythmia, COVID-19, drug repositioning, hydroxychloroquine, severe acute respiratory syndrome coronavirus-2

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]